Acadia Pharmaceuticals ACAD Enterprise value

Enterprise value at other companies

BiogenBIIB

$38.17B+70.8%

Neurocrine BiosciencesNBIX

$13.41B+18.5%

MapLight Therapeutics, Inc.MPLT

$812.61M—

Taysha Gene Therapies, Inc.TSHA

$1.08B+368%

Zevra Therapeutics, Inc.ZVRA

$703.89M+36.7%

LBR

LB Pharmaceuticals IncLBRX

$389.92M—

FAQ

What is Acadia Pharmaceuticals's enterprise value?

Acadia Pharmaceuticals (ACAD) reported enterprise value of $4.02B in Q2 2026.

How has Acadia Pharmaceuticals's enterprise value changed year-over-year?

Acadia Pharmaceuticals's enterprise value increased by 13.2% year-over-year, from $3.55B to $4.02B.

What is the long-term trend for Acadia Pharmaceuticals's enterprise value?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's enterprise value has grown at a -12.0% compound annual growth rate (CAGR), from $8.32B to $4.39B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.